Nintedanib

CAS 656247-17-5

About the API

Technology Synthetic Organic Chemistry
Therapeutic category Respiratory
Available formulations Oral Solid

General Information

Nintedanib esylate is a drug for the treatment of a lung disease called idiopathic pulmonary fibrosis (IPF). IPF may develop as a result of an aberrant wound-healing response in the lungs. Scar tissue replaces normal lung tissue, thickens and stiffens over time, compromising lung function, and resulting in progressive respiratory failure. In addition, nintedanib in combination with docetaxel is approved in Europe for the second-line treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumor type. Adenocarcinoma is the most common type of lung cancer and many patients are diagnosed in an advanced stage.

 

Developed by Boehringer Ingelheim, nintedanib was approved by in the United States and Europe in 2014 under the trade name Ofev and Vargatef, respectively. It was granted orphan drug, fast track, and breakthrough designations. It is produced through multi-step chemical synthesis.